Interferons Global Market Report 2024

The interferons market size has grown steadily in recent years. It will grow from $9.17 billion in 2023 to $9.54 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. During the historic period, growth was propelled by factors such as viral infections, advancements in antiviral therapies, developments in cancer treatment, and focus on autoimmune diseases.

The interferons market size is expected to see steadily grown in the next few years. It will grow to $11.98 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. Anticipated growth in the forecast period is driven by advancements in immunotherapy, the emergence of precision medicine, preparedness for viral outbreaks, exploration of drug combinations, and developments in gene therapy. Key trends expected in this period encompass broader applications, innovation in biopharmaceuticals, exploration of interferon combinations, and the continued expansion of personalized medicine.

The surge in cancer cases is anticipated to fuel the growth of the interferon market. Cancer, characterized by abnormal cell growth and potential spread, finds treatment in interferons. These agents, used across various cancer types like melanoma, Kaposi's sarcoma, and certain leukemias, bolster the body's immune response against cancer cells. As per a January 2022 report from the American Cancer Society, an estimated 1.9 million new cancer cases and 609,360 anticipated cancer-related deaths are expected in the US for 2022. This includes projections for pediatric and teenage cancer cases, driving the expansion of the interferon market.

The global market for interferon drugs is poised for rapid growth due to the rising incidence of chronic diseases such as hepatitis-B, hepatitis-C, cancer, and multiple sclerosis. Interferons are instrumental in combinational therapies and advancements in drug delivery systems. Innovations in treating diseases like hepatitis-C involve combining interferon-alpha with other drugs, yielding significant virologic improvements. However, the poor gastrointestinal stability of interferon-alpha necessitates parenteral administration, leading to severe side effects. Studies indicate that nanoencapsulation within nanoparticles could enhance oral bioavailability. These trends in combinational therapies and novel drug delivery systems are expected to drive the interferon market, with ongoing exploration for COVID-19 treatment applications. Biologics therapy, expensive and financially burdensome for healthcare systems, has prompted a closer look at biosimilars. Increasing disease prevalence has led local pharmaceutical companies to produce interferon biosimilar medications as cost-effective alternatives to original brands. Initially explored as antivirals, interferons are now pivotal in anti-HBV and anti-HCV therapy. The therapeutic promise of interferon biosimilars for hepatitis and cancer, alongside ongoing studies for prophylactic or therapeutic effectiveness against SARS, influenza, or other virus pandemics, fuels the adoption of interferon biosimilars over costly biologics.

Major companies in the interferons market focus on new product development, like Ropeginterferon alfa-2b-njft injections, aiming to expand customer bases and revenue. Ropeginterferon alfa-2b-njft, used in treating chronic diseases and viral infections, gained FDA approval in November 2021. PharmaEssentia Corporation's Besremi (ropeginterferon alfa-2b-njft) injection, the first FDA-approved medication for polycythemia vera suitable for all patients regardless of treatment history, marks a significant milestone. Administered via subcutaneous injections once every two weeks, it reduces blood cell production in the bone marrow by binding to specific receptors.

Bayer's collaboration with Curadev Pvt. Ltd., an India-based drug discovery company, focuses on Curadev’s Stimulator of Interferon Genes (STING) antagonist program. This partnership aims to discover new drug candidates for lung diseases, cardiovascular diseases, and other inflammatory conditions. STING antagonists hold promise in activating the innate immune system for treating auto-inflammatory diseases.

Major companies operating in the interferons market include Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Biogen Inc., Bayer AG, Zydus Cadila Health Care Limited, Novartis AG, Pfizer Inc., Biosidus S.A., Nanogen Biopharmaceutical Co. Ltd., Amega Biotech Inc., Rhein Minapharm Biogenetics S.A.E., PROBIOMED S.A. De C.V., Schering-Plough Corporation, 3SBio Inc., AbbVie Inc., Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline PLC, Johnson & Johnson, Novo Nordisk A/S, Sanofi S.A., Shire PLC, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Biocad, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited.

North America was the largest region in the interferons market in 2023. Middle East is expected to be the fastest-growing region in the interferons market during the forecast period. The regions covered in the interferons market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the interferons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary types of interferons include interferon alpha, interferon beta, and interferon gamma. Interferon alpha is a cytokine created by the innate immune system as a response to various environmental exposures, such as viral infections. These products are distributed through hospital pharmacies, online pharmacies, retail pharmacies, and other channels, and they are utilized in treating conditions like hepatitis B, hepatitis C, melanoma, leukemia, multiple sclerosis, and renal cell carcinoma.

The interferons market research report is one of a series of new reports provides interferons market statistics, including the interferons industry's global market size, regional shares, competitors with an interferons market share, detailed interferons market segments, market trends, and opportunities, and any further data you may need to thrive in the interferons industry. This interferons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The interferons market consists of sales of polypeptides, cytokine, and cell-surface receptors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.